Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOSi in Biofilm-Associated Recalcitrant Chronic Rhinosinusitis
NCT04163978Phase 2Completed
- Sponsor
- SaNOtize
- Start
- Oct 2019
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitric oxide in chronic rhinosinusitis (CRS), sponsored by SaNOtize. Primary endpoint: Sino-Nasal Outcome Test at 63 days. Started Oct 2019; status: completed.
02
Drugs
nitric oxide
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT04163978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163978.